Crowderlloyd8433

INTRODUCTION Digital billboards (DBs) are a competing factor for attracting drivers' attention; evidence shows that DBs may cause crashes and vehicle conflicts because they catch drivers' attention. Carboplatin manufacturer Because of the complexity of a system that includes road conditions, driver features, and environmental factors, it is simply not possible to identify relationships between these factors. Thus, the present study was conducted to provide a well-organized procedure to analyze the effects of DBs on drivers' behavior and measure factors responsible for drivers' distraction in Babol, Iran, as a case study. METHOD Corresponding data were collected through a Naturalistic Driving Study (NDS) of 78 participants when facing DBs (1,326 samples). These data were analyzed by applying structural equation modeling (SEM) to concurrently recognize relationships between endogenous and exogenous variables. Human, environmental, and road factors were determined as exogenous latent variables in a model to evaluate their influences on drivers' distraction as an endogenous variable. RESULTS The results showed that road, environmental, and human factors reciprocally interact with drivers' distraction, although the estimated coefficient of human factors was more of a factor than that of the other groups. Furthermore, younger drivers, beginner drivers, and male drivers (as human factors); night and unclear weather like a rainy day (as environmental factors); and installing DBs at complicated traffic positions like near-intersections (as road factors) were determined to be the main factors that increase the possibility of drivers' distraction. Finally, model assessment was suggested using the goodness-of-fit indices. BACKGROUND Despite national calls to develop gender-specific interventions for women with opioid use disorder (OUD) with co-occurring trauma and post-traumatic stress disorder (PTSD) symptoms, there remains a dearth of research on what modalities or treatment components would be most feasible for this population. This study interviewed women with OUD receiving medication assisted treatment and addiction treatment providers to explore (a) experiences of barriers to receiving trauma treatment, and (b) both the perceptions and desired design of a prospective technology-delivered, trauma-informed treatment for women with OUD. METHODS Women with lifetime OUD (n = 11) and providers (n = 5) at two community substance use clinics completed semi-structured interviews. Interviews were transcribed, coded, and analyzed in NVivo v11 using a grounded theory approach. Women also completed a demographic form and clinical measures. RESULTS Clients were primarily women with children reporting histories of multiple trauma exposures, high PTSD symptoms, and polysubstance use. Two themes emerged among clients and one among providers regarding barriers to trauma treatment. Regarding the feasibility and desired attributes of a technology-based intervention, six themes emerged among clients and providers, respectively. CONCLUSIONS Themes suggest a high interest by clients and providers for a technology-delivered, trauma informed treatment available by smartphone. Utilizing technology as an adjunct to care, without reducing face-to-face therapy, was important to both clients and providers. INTRODUCTION Transgender (trans) people experience stressors related to their minority status which have been associated with increased rates of psychoactive substance use and related harm. Despite this, there is a paucity of evidence relating to the treatment needs of trans people who use psychoactive substances, beyond a small body of literature describing a culture of transphobic hostility in general substance misuse services. This paper aims to describe and compare psychoactive substance misuse help-seeking among trans and cisgender (cis) participants from a large multi-national cross-sectional survey. METHODS Over 180,000 participants, recruited from the world's largest annual survey of drug use - the Global Drug Survey - during 2018 and 2019, reported use of a range of psychoactive substances in the preceding 12 months. Five gender groups (118,157 cis men, 64,319 cis women, 369 trans men, 353 trans women and 1857 non-binary people) were compared on items relating to the desire to use less psychoactive s clients. BACKGROUND As the burden of opioid use disorder (OUD) increases in the United States, manifold federal and state initiatives have sought to increase access to treatment for OUD, which includes behavioral and pharmaceutical treatment modalities. Although the evidence base for outpatient treatment for OUD-including medications for opioid use disorder-is substantial, few studies have examined the risk factors for fatality during treatment for OUD. METHODS Treatment Episode Data Set-Discharges (TEDS-D) data were used to evaluate correlates of death during outpatient treatment for OUD in 2016. To determine the correlates of mortality during an outpatient treatment for OUD, we constructed a pooled logistic regression model, stratified by use of medication for opioid use disorder (MOUD), to control for the duration of time in treatment and to identify the independent characteristics that may lead to differences in the odds of mortality during treatment. FINDINGS 1861 (0.8%) of 235,745 outpatient treatment episodes for OUD included in our analysis resulted in fatality. Many factors correlated with death during treatment were similar for individuals who did and did not receive MOUD. However, non-White race was only significantly associated with decreases in fatality in non-MOUD treatment episodes. Male sex and reported intravenous drug use at admission were associated with fatality only for treatment episodes that did not involve MOUD. CONCLUSIONS In this national study of outpatient treatment episodes for OUD, we found differences in age, sex, region, drug use history, treatment setting, and treatment history significantly affected the risk of death during treatment. As more people become engaged with treatment, facilities should work toward delivering optimal treatment for all patients regardless of personal characteristics.